Vimarsana
Biggest News Aggregation in the World

Network Trials Unit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Network Trials Unit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Network Trials Unit Today - Breaking & Trending Today

EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023 - Vimarsana News

EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023

/PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings on its...

With early Alzheimer's in the family, these sisters decided to test for the gene - Vimarsana News

With early Alzheimer's in the family, these sisters decided to test for the gene

For some people, a rare genetic mutation makes dementia inescapable. Three sisters have decided to confront fate with a genetic test and have joined a research project on possible treatments.

Source: kanw.com
A gene test for early Alzheimer's raises questions for families : Shots - Vimarsana News

A gene test for early Alzheimer's raises questions for families : Shots

For some people, a rare genetic mutation makes dementia inescapable. Three sisters have decided to confront fate with a genetic test and have joined a research project on possible treatments.

Source: npr.org
Early Onset Alzheimer's Trial - Vimarsana News

Early Onset Alzheimer's Trial

Washington University conducted several trials of a rare, inherited form of Alzheimer's that typically develops in a person's 50s, 40s...

Eisai To Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State Symposium, and Other Pipeline Assets at the AD/PD™ 2022 Annual Meeting - Vimarsana News

Eisai To Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State Symposium, and Other Pipeline Assets at the AD/PD™ 2022 Annual Meeting

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present research from its robust Alzheimer's...